History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Look AHEAD Research Group, Lewis Cora E, Bantle John P, Bertoni Alain G, Blackburn George, Brancati Frederick L, Bray George A, Cheskin Lawrence J, Curtis Jeffrey M, Egan Caitlin, Evans Mary, Foreyt John P, Ghazarian Siran, Barone Gibbs Bethany, Glasser Stephen P, W Gregg Edward, Hazuda Helen P, Hesson Louise, Hill James O, Horton Edward S, Hubbard Van S, Jakicic John M, Jeffery Robert W, Johnson Karen C, Kahn Steven E, Kitabchi Abbas E, Kitzman Dalane, Knowler William C, Lipkin Edward, Michaels Sara, Montez Maria G, Nathan David M, Nyenwe Ebenezer, Patricio Jennifer, Peters Anne, Pi-Sunyer Xavier, Pownall Henry, Reboussin David M, Ryan Donna H, Wadden Thomas A, Wagenknecht Lynne E, Wyatt Holly, Wing Rena R, Yanovski Susan Z
Аннотация
METHODS: This study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes.
RESULTS: Interaction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group.
CONCLUSIONS: Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.